Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
Go back to Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)| Empire Insurance Co (NASDAQ: EIGR) | Delayed: 1.73 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.73 | 52 Week High | $23.10 | |||
| Open | $63.25 | 52 Week Low | $10.71 | |||
| Day High | $1.73 | P/E | N/A | |||
| Day Low | $1.73 | EPS | $0.00 | |||
| Volume | 457,358 | |||||
